These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38500407)

  • 41. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites.
    Cruz-Zetina G; del Rio-Rodriguez R; Ramos-Ligonio A; López R; Monteon V
    Am J Trop Med Hyg; 2012 Oct; 87(4):671-4. PubMed ID: 22890036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benznidazole therapy in Trypanosoma cruzi-infected mice blocks thymic involution and apoptosis of CD4+CD8+ double-positive thymocytes.
    Olivieri BP; Farias-De-Oliveira DA; Araujo-Jorge TC; Cotta-de-Almeida V
    Antimicrob Agents Chemother; 2005 May; 49(5):1981-7. PubMed ID: 15855522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection.
    Cruz-Chan JV; Villanueva-Lizama LE; Versteeg L; Damania A; Villar MJ; González-López C; Keegan B; Pollet J; Gusovsky F; Hotez PJ; Bottazzi ME; Jones KM
    Sci Rep; 2021 Feb; 11(1):3222. PubMed ID: 33547365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.
    Álvarez MG; Hernández Y; Bertocchi G; Fernández M; Lococo B; Ramírez JC; Cura C; Albizu CL; Schijman A; Abril M; Sosa-Estani S; Viotti R
    Antimicrob Agents Chemother; 2016 Feb; 60(2):833-7. PubMed ID: 26596935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection.
    Santos DM; Martins TA; Caldas IS; Diniz LF; Machado-Coelho GL; Carneiro CM; Oliveira Rde P; Talvani A; Lana M; Bahia MT
    Acta Trop; 2010 Feb; 113(2):134-8. PubMed ID: 19854145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.
    Olivieri BP; Cotta-De-Almeida V; Araújo-Jorge T
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3790-6. PubMed ID: 12435678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection.
    Davies C; Simonazzi A; Micheloud JF; Ragone PG; Cid AG; Negrette OS; Bermúdez JM; Parada LA
    J Parasitol; 2020 Jun; 106(3):323-333. PubMed ID: 32369594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
    Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
    Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thioridazine aggravates skeletal myositis, systemic and liver inflammation in Trypanosoma cruzi-infected and benznidazole-treated mice.
    Mendonça AAS; Gonçalves-Santos E; Souza-Silva TG; González-Lozano KJ; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
    Int Immunopharmacol; 2020 Aug; 85():106611. PubMed ID: 32447223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
    Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
    ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trypanosoma cruzi: chemotherapy with benznidazole in mice inoculated with strains from Paraná state and from different endemic areas of Brazil.
    Toledo MJ; Guilherme AL; da Silva JC; de Gasperi MV; Mendes AP; Gomes ML; de Araújo SM
    Rev Inst Med Trop Sao Paulo; 1997; 39(5):283-90. PubMed ID: 9661307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the Western Brazilian Amazon.
    Teston APM; Fernandes NS; Abegg CP; de Abreu AP; Sarto MPM; Gomes ML; Toledo MJO
    Exp Parasitol; 2021 Sep; 228():108136. PubMed ID: 34280400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.
    Novaes RD; Sartini MV; Rodrigues JP; Gonçalves RV; Santos EC; Souza RL; Caldas IS
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3355-64. PubMed ID: 27001816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole.
    Murta SM; Romanha AJ
    Parasitology; 1998 Feb; 116 ( Pt 2)():165-71. PubMed ID: 9509026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benznidazole, itraconazole, and their combination for the treatment of chronic experimental Chagas disease in dogs.
    Cunha ELA; Torchelsen FKVDS; Fonseca KDS; Sousa LRD; Vieira PMA; Carneiro CM; Pinto KMC; Torres RM; Lana M
    Exp Parasitol; 2022 Jul; 238():108266. PubMed ID: 35490799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.